Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Wisconsin Technology Today.
Press releases published on July 29, 2025
Kneat to Announce 2025 Second-Quarter Financial Results August 5, 2025
GlobeNewswire
·
July 29, 2025
LIMERICK, Ireland, July 29, 2025 (GLOBE NEWSWIRE) -- kneat.com, inc. (TSX: KSI) (OTC: KSIOF) (“Kneat” or the “Company”) a leader in digitizing and automating validation and quality processes, announced today that the Company will release its financial …
Rakovina Therapeutics Announces Stock Option Grants
GlobeNewswire
·
July 29, 2025
VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (FSE: 7JO0) (the “Company” or “Rakovina”), a biopharmaceutical company advancing cancer therapies through artificial intelligence (AI)-powered drug …
Axonius Acquires Medical Device Security Specialist Cynerio for More Than $100 Million to Target Healthcare Market
GlobeNewswire
·
July 29, 2025
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- Axonius, the global leader in cyber asset intelligence, today announced that it has acquired Cynerio, a pioneer in medical device security for more than $100 million in a cash and stock transaction. The …
Silvaco to Acquire Mixel, Inc. a Provider of Low-Power, High-Performance Mixed-Signal Connectivity IP Solutions
GlobeNewswire
·
July 29, 2025
SANTA CLARA, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Silvaco Group, Inc. (“Silvaco”) (NASDAQ: SVCO), a provider of TCAD, EDA software, and SIP solutions that enable semiconductor design and digital twin modeling through AI software and innovation, today …
DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report
GlobeNewswire
·
July 29, 2025
Châtillon, France, July 29, 2025 DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage …
DBV Technologies publie son Rapport Financier Semestriel 2025 ― Modalités de mise à disposition ou de consultation
GlobeNewswire
·
July 29, 2025
Châtillon, France, le 29 juillet 2025 DBV Technologies publie son Rapport Financier Semestriel 2025 ― Modalités de mise à disposition ou de consultation DBV Technologies (Euronext : DBV – ISIN : FR0010417345 - Nasdaq : DBVT), une société biopharmaceutique …
Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025
GlobeNewswire
·
July 29, 2025
DURHAM, N.C., July 29, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2025 …
DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results
GlobeNewswire
·
July 29, 2025
Châtillon, France, July 29, 2025 DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, …
DBV Technologies publie ses résultats financiers du 2ème trimestre et 1er semestre 2025
GlobeNewswire
·
July 29, 2025
Châtillon, France, le 29 juillet 2025 DBV Technologies publie ses résultats financiers du 2ème trimestre et 1er semestre 2025 DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq Stock Market : DBVT-CUSIP : 23306J309), société biopharmaceutique …
Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)
GlobeNewswire
·
July 29, 2025
– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) – – Early PFS data show a trend favoring 30mg onvansertib dose arm vs. control arm – – Onvansertib …
Pulmonx to Present at the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire
·
July 29, 2025
REDWOOD CITY, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the company will be presenting at the Canaccord …
Varonis Announces Second Quarter 2025 Financial Results
GlobeNewswire
·
July 29, 2025
Annual recurring revenues grew 19% year-over-year SaaS ARR as a percentage of total ARR was approximately 69% Year-to-date cash from operations generated $89.3 million vs. $68.4 million last year Year-to-date free cash flow generated $82.7 million vs. $67. …
Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025
GlobeNewswire
·
July 29, 2025
SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2025 earnings conference call at 4:30pm ET on Tuesday, Aug. 5, 2025. The …
Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update
GlobeNewswire
·
July 29, 2025
- Appointed Dr. Roger Sidhu as Chief Medical Officer - - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) - - Announced …
EXL announces $125 million accelerated share repurchase program
GlobeNewswire
·
July 29, 2025
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- EXL [NASDAQ: EXLS], a global data and AI company, today announced that, as part of its capital allocation program, it has entered into an accelerated share repurchase agreement (the “ASR”) with Citibank, N.A. to …
Larimar Therapeutics Announces Proposed Underwritten Public Offering
GlobeNewswire
·
July 29, 2025
BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an …
Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints
GlobeNewswire
·
July 29, 2025
- Primary Endpoint Analysis Confirms Favorable Tolerability Profile of ATI-2138 Without Certain Risks Associated with Other Agents in the Class - - Efficacy Results Show Comparable Outcomes to Approved Therapies with Potential for Improved Tolerability, …
EXL Reports 2025 Second Quarter Results
GlobeNewswire
·
July 29, 2025
2025 Second Quarter Revenue of $514.5 Million, up 14.7% year-over-year Q2 Diluted EPS (GAAP) of $0.40, up 43.9% from $0.28 in Q2 of 2024 Q2 Adjusted Diluted EPS (Non-GAAP) (1) of $0.49, up 20.3% from $0.40 in Q2 of 2024 NEW YORK, July 29, 2025 (GLOBE …
Qorvo® Announces Fiscal 2026 First Quarter Financial Results
GlobeNewswire
·
July 29, 2025
GREENSBORO, N.C., July 29, 2025 (GLOBE NEWSWIRE) -- Qorvo® (Nasdaq:QRVO), a leading global provider of connectivity and power solutions, today announced financial results for the Company’s fiscal 2026 first quarter ended June 28, 2025. On a GAAP basis, …
Inventiva Reports Preliminary 2025 First-Half Financial Information¹
GlobeNewswire
·
July 29, 2025
Cash and cash equivalents at €122.1 million and €24.6 million in short-term deposits2 as of June 30, 2025 Revenues of €4.5 million recorded in H1 2025 Daix (France), New York City (New York, United States), July 29, 2025 – Inventiva (Euronext Paris and …